Involvement of p21 waf1/cip1 expression in the cytotoxicity of the potent histone deacetylase inhibitor spiruchostatin B towards susceptible NALM-6 human B cell leukemia cells

International Journal of Oncology

Volumn 40, Issue 5, 2012, Pages 1391-1396

  Kanno, Syu Ichi ^a   Maeda, Naoyuki ^a   Tomizawa, Ayako ^a   Yomogida, Shin ^a   Katoh, Tadashi ^a   Ishikawa, Masaaki ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Histone deacetylase inhibitor; Human leukemia cell lines; NALM 6; p21 waf1 cip1; Spiruchostatin

Indexed keywords

ANTILEUKEMIC AGENT; BUTYRIC ACID; CASPASE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PROTEIN P21; SPIRUCHOSTATIN B; TRICHOSTATIN A; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DEPSIPEPTIDE; HDAC1 PROTEIN, HUMAN; HISTONE DEACETYLASE 1;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL CYCLE CHECKPOINT; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUCLEAR SHAPE; PATHOLOGY; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL NUCLEUS SHAPE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA, B-CELL; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; UP-REGULATION;

EID: 84860314336     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1323     Document Type: Article

References (34)

1. Abujamra AL, Dos Santos MP, Roesler R, Schwartsmann G and Brunetto AL: Histone deacetylase inhibitors: a new perspective for the treatment of leukemia. Leuk Res 34: 687-695, 2010.
2. Leone G, D'Alo F, Zardo G, Voso MT and Nervi C: Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. Curr Med Chem 15: 1274-1287, 2008. (Pubitemid 351997797)
3. Paris M, Porcelloni M, Binaschi M and Fattori D: Histone deacetylase inhibitors: from bench to clinic. J Med Chem 51: 1505-1529, 2008. (Pubitemid 351438836)
4. Wagner JM, Hackanson B, Lubbert M and Jung M: Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 1: 117-136, 2010.
5. Davie JR: Inhibition of histone deacetylase activity by butyrate. J Nutr 133: S2485-S2493, 2003.
6. Yoshida M, Kijima M, Akita M and Beppu T: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174-17179, 1990.
7. Elaut G, Torok G, Vinken M, et al: Major phase I biotransformation pathways of Trichostatin a in rat hepatocytes and in rat and human liver microsomes. Drug Metab Dispos 30: 1320-1328, 2002. (Pubitemid 35397033)
8. Ueda H, Nakajima H, Hori Y, et al: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 47: 301-310, 1994. (Pubitemid 24106520)
9. Byrd JC, Marcucci G, Parthun MR, et al: A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105: 959-967, 2005. (Pubitemid 40170861)
10. Masuoka Y, Nagai A, Shin-Ya K, et al: Spiruchostatins A and B, novel gene expression-enhancing substances produced by Pseudomonas sp. Tetrahedron Lett 42: 41-44, 2001. (Pubitemid 32011701)
11. Crabb SJ, Howell M, Rogers H, et al: Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A. Biochem Pharmacol 76: 463-475, 2008.
12. Davidson SM, Townsend PA, Carroll C, et al: The transcriptional coactivator p300 plays a critical role in the hypertrophic and protective pathways induced by phenylephrine in cardiac cells but is specific to the hypertrophic effect of urocortin. Chembiochem 6: 162-170, 2005. (Pubitemid 40128649)
13. Narita K, Kikuchi T, Watanabe K, et al: Total synthesis of the bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5″-epi- spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity. Chemistry 15: 11174-11186, 2009.
14. Han JW, Ahn SH, Kim YK, et al: Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C. J Biol Chem 276: 42084-42090, 2001.
15. Fournel M, Trachy-Bourget MC, Yan PT, et al: Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res 62: 4325-4330, 2002. (Pubitemid 34827289)
16. Archer SY, Meng S, Shei A and Hodin RA: p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95: 6791-6796, 1998.
17. Sambucetti LC, Fischer DD, Zabludoff S, et al: Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274: 34940-34947, 1999. (Pubitemid 129509542)
18. Gui CY, Ngo L, Xu WS, Richon VM and Marks PA: Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101: 1241-1246, 2004. (Pubitemid 38182673)
19. Ocker M and Schneider-Stock R: Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 39: 1367-1374, 2007. (Pubitemid 47031035)
20. Takizawa T, Watanabe K, Narita K, Oguchi T, Abe H and Katoh T: Total synthesis of spiruchostatin B, a potent histone deacetylase inhibitor, from a microorganism. Chem Commun (Camb): 1677-1679, 2008. (Pubitemid 351441902)
21. Kanno S, Kakuta M, Kitajima Y, et al: Preventive effect of trimidox on oxidative stress in U937 cell line. Biol Pharm Bull 30: 994-998, 2007. (Pubitemid 46708638)
22. Kanno S, Hiura T, Ohtake T, et al: Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells. Clin Chim Acta 377: 144-149, 2007. (Pubitemid 44908246)
23. Kanno S, Higurashi A, Watanabe Y, Shouji A, Asou K and Ishikawa M: Susceptibility to cytosine arabinoside (Ara-C)-induced cytotoxicity in human leukemia cell lines. Toxicol Lett 152: 149-158, 2004. (Pubitemid 39061766)
24. Lemaire C, Andreau K, Souvannavong V and Adam A: Specific dual effect of cycloheximide on B lymphocyte apoptosis: involvement of CPP32/caspase-3. Biochem Pharmacol 58: 85-93, 1999. (Pubitemid 29246077)
25. Tan J, Cang S, Ma Y, Petrillo RL and Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 3: 5, 2010.
26. Kim MS, Kwon HJ, Lee YM, et al: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437-443, 2001. (Pubitemid 32298546)
27. Marquard L, Poulsen CB, Gjerdrum LM, et al: Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 54: 688-698, 2009.
28. Choi JH, Kwon HJ, Yoon BI, et al: Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 92: 1300-1304, 2001. (Pubitemid 34036893)
29. Sasaki H, Moriyama S, Nakashima Y, et al: Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 46: 171-178, 2004. (Pubitemid 39330411)
30. Zhang Z, Yamashita H, Toyama T, et al: Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat 94: 11-16, 2005. (Pubitemid 41416937)
31. Peart MJ, Tainton KM, Ruefli AA, et al: Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63: 4460-4471, 2003. (Pubitemid 36951018)
32. Abbas T and Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414, 2009.
33. Arts J, Angibaud P, Marien A, et al: R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer 97: 1344-1353, 2007. (Pubitemid 350114783)
34. Roman-Gomez J, Castillejo JA, Jimenez A, et al: 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 99: 2291-2296, 2002. (Pubitemid 34525411)